Posology : מינונים

4.2. Posology and method of administration
This specific application form should only be used if a quick onset of pain relief is needed or if an oral application or an application via suppository is not possible. Generally the treatment should comprise one single injection for therapy initiation only.
For all patients the appropriate dosing regimen should be based upon individual response to treatment.
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4.).

Pain
Recommended dose: 8 mg intravenous (IV) or intramuscular (IM) injection. Daily dose should not exceed 16 mg.
Some patients may need a further 8 mg given during the first 24 hours.

Special populations
Paediatric population
Lornoxicam is not recommended for use in children and adolescents below 18 years of age because of a lack of data on safety and efficacy.

Elderly
No special dosage modification is required for elderly patients above 65 years of age unless renal or hepatic function is impaired, but Lornoxicam should be administered with caution as gastrointestinal adverse effects are less well tolerated in this group (see section 4.4).

Renal impairment
For patients with mild to moderate renal impairment dose reduction should be considered (see section 4.4).
Lornoxicam is contraindicated in patients with severe renal impairment (see section 4.3).

Hepatic impairment
For patients with moderate hepatic impairment dose reduction should be considered (see section 4.4).
Lornoxicam is contraindicated in patients with severe hepatic impairment (see section 4.3).
Method of Administration

The medicinal product is for single use only.

The route of administration is IV or IM injection. When given as IV injection, the time of injection should be at least 15 seconds, and for IM injection, at least 5 seconds.

After preparation of the solution, the needle should be changed. For IM injection, a sufficiently long needle for a deep intramuscular injection is necessary.

For further instructions on handling of the product before administration, see section 6.6.